Alzamend Neuro (ALZN) Other Non Operating Income (2021)
Alzamend Neuro's (ALZN) quarterly Other Non Operating Income came in at $62418.0 in Q1 2021.
Powered by 
Analysis
Alzamend Neuro (ALZN) Other Non Operating Income (2021) Analysis & Trends
Alzamend Neuro has disclosed Other Non Operating Income across 1 years of filings, most recently posting $62418.0 for Q1 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 209.94 Bn | 195.95 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.74 Bn | 176.57 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.05 Bn | 124.20 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.43 Bn | 74.44 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.23 Bn | 56.04 Bn | 1.37 Bn |
| 6 | Moderna | 53.42 Bn | 48.28 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.77 Bn | 30.47 Bn | 992.69 Mn |
| 8 | Biogen | 31.62 Bn | 30.33 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Alzamend Neuro | 5.57 Mn | 5.57 Mn | - |